サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1655531

抗生物質の世界市場

Antibiotics

出版日
ページ情報
英文 266 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.06円
抗生物質の世界市場
出版日: 2025年02月14日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 266 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

抗生物質の世界市場は2030年までに503億米ドルに達する見込み

2024年に419億米ドルと推定される抗生物質の世界市場は、2024年から2030年にかけてCAGR 3.1%で成長し、2030年には503億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるペニシリンは、CAGR 3.3％を記録し、分析期間終了時には157億米ドルに達すると予想されます。セファロスポリンセグメントの成長率は、分析期間中CAGR 3.8%と推定されます。

米国市場は112億米ドルと推定、中国はCAGR 4.9％で成長予測

米国の抗生物質市場は、2024年に112億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに102億米ドルの市場規模に達すると予測され、分析期間2024-2030年のCAGRは4.9%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ2.0％と2.5％と予測されています。欧州では、ドイツがCAGR 2.5%で成長すると予測されています。

世界の抗生物質市場- 主要動向と促進要因まとめ

抗生物質：現代医療の礎石

抗生物質の発見と開発は医学に革命をもたらし、細菌感染症の治療を一変させ、無数の命を救いました。年にアレクサンダー・フレミングによって発見されたペニシリンは、最初の真の抗生物質であり、治療における新しい時代の幕開けとなりました。抗生物質の登場以前は、軽微な感染症が命取りになることも多く、細菌性疾患の治療の選択肢は限られていました。抗生物質のイントロダクションは、肺炎、結核、敗血症など幅広い感染症に有効な治療法を提供し、死亡率を劇的に低下させました。長年にわたり、セファロスポリン、テトラサイクリン、マクロライドといった新しいクラスの抗生物質が開発されたことで、臨床医が利用できる武器が拡大し、さまざまな細菌感染症の治療が、より高い特異性と有効性をもって行えるようになりました。この革命により、個人の健康状態が改善されただけでなく、外科手術や慢性疾患の管理の進歩も促進されました。

抗生物質の異なるクラスとそのメカニズムとは？

抗生物質は、その化学構造と作用機序により、いくつかのカテゴリーに分類されます。ペニシリンやセファロスポリンを含むβ-ラクタム系抗菌薬は、細菌の細胞壁合成を破壊し、細胞溶解と死滅に導きます。テトラサイクリン系抗菌薬は細菌のリボソームに結合してタンパク質合成を阻害し、必須タンパク質の産生を阻止します。エリスロマイシンなどのマクロライド系抗菌薬も細菌のリボソームを標的とするが、異なるメカニズムで作用するため、異なるスペクトルの細菌に有効です。アミノグリコシド系抗菌薬も同様にタンパク質合成を阻害するが、特に好気性グラム陰性菌に有効です。シプロフロキサシンのようなフルオロキノロン系抗菌薬は、細菌のDNAジャイレースとトポイソメラーゼIVを標的としてDNA複製を阻害します。抗生物質の各クラスは独自の利点を持ち、特定のタイプの細菌感染を標的として使用されるため、よりオーダーメイドで効果的な治療が可能になります。

抗生物質耐性にはどのような課題がありますか？

抗生物質耐性は、現代医学が直面している最も重大な課題の1つです。人間の医療や農業における抗生物質の乱用や誤用は、耐性菌の開発を加速させています。細菌は抗生物質にさらされると、薬剤を不活性化する酵素を産生したり、薬剤の標的部位を変化させたり、薬剤を細胞外に送り出すなど、生き残るためのメカニズムを進化させます。耐性感染症は治療が難しく、より強力な抗生物質を必要とし、治療期間も長くなり、場合によっては死亡率も増加します。メチシリン耐性黄色ブドウ球菌（MRSA）やカルバペネム耐性腸内細菌科細菌（CRE）などの多剤耐性菌の蔓延は、この問題の緊急性を強調しています。抗生物質耐性と闘うための取り組みには、新しい抗生物質の開発、既存の抗生物質の使用を最適化するための抗生物質スチュワードシップ・プログラムの実施、抗生物質の誤用を減らし代替療法の研究を促進するための世界の取り組みなどがあります。

抗生物質市場の成長を促進する要因は？

抗生物質市場の成長は、いくつかの要因によって牽引されています。特に、人口密度が高く、ヘルスケアへのアクセスが限られている発展途上地域における細菌感染症の開発の増加は、重要な促進要因です。診断技術の進歩により、細菌性病原体の検出と同定が改善され、より的を絞った抗生物質療法につながっています。複数の抗生物質に耐性を持つことが多い院内感染の増加により、より新しく効果的な治療法の開発と使用が必要となっています。さらに、現在進行中の研究開発では、既存の耐性問題を克服するために、独自の作用機序を持つ新規の抗生物質の発見に注力しています。政府や医療機関からの規制支援や資金援助も、新しい抗生物質の研究、承認、商業化を促進することで、抗生物質市場を強化しています。さらに、新興国におけるヘルスケアインフラの拡大と医療費の増加は、抗生物質へのアクセスと需要の拡大に寄与しており、市場成長の原動力となっています。

セグメント

薬剤クラス（ペニシリン、セファロスポリン、マクロライド、フルオロキノロン、テトラサイクリン、薬剤クラス別）;投与経路（非経口、経口、その他の投与経路）

調査対象企業の例（注目の合計209社）

  • Abbott Laboratories, Inc.
  • Allergan PLC
  • Aurobindo Pharma Ltd.
  • Bayer AG
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Lupin Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis International AG
  • Pfizer, Inc.
  • Sanofi
  • Shionogi, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • スペイン
  • ロシア
  • その他欧州
  • アジア太平洋
  • オーストラリア
  • インド
  • 韓国
  • その他アジア太平洋地域
  • ラテンアメリカ
  • アルゼンチン
  • ブラジル
  • メキシコ
  • その他ラテンアメリカ
  • 中東
  • イラン
  • イスラエル
  • サウジアラビア
  • アラブ首長国連邦
  • その他中東
  • アフリカ

第4章 競合

目次
Product Code: MCP-1705

Global Antibiotics Market to Reach US$50.3 Billion by 2030

The global market for Antibiotics estimated at US$41.9 Billion in the year 2024, is expected to reach US$50.3 Billion by 2030, growing at a CAGR of 3.1% over the analysis period 2024-2030. Penicillin, one of the segments analyzed in the report, is expected to record a 3.3% CAGR and reach US$15.7 Billion by the end of the analysis period. Growth in the Cephalosporin segment is estimated at 3.8% CAGR over the analysis period.

The U.S. Market is Estimated at US$11.2 Billion While China is Forecast to Grow at 4.9% CAGR

The Antibiotics market in the U.S. is estimated at US$11.2 Billion in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$10.2 Billion by the year 2030 trailing a CAGR of 4.9% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 2.0% and 2.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 2.5% CAGR.

Global Antibiotics Market - Key Trends and Drivers Summarized

Antibiotics: The Cornerstone of Modern Medicine

The discovery and development of antibiotics revolutionized medicine, transforming the treatment of bacterial infections and saving countless lives. Penicillin, discovered by Alexander Fleming in 1928, was the first true antibiotic, marking the beginning of a new era in medical treatment. Before antibiotics, minor infections often turned deadly, and there were limited options for treating bacterial diseases. The introduction of antibiotics provided effective treatments for a wide range of infections, including pneumonia, tuberculosis, and sepsis, dramatically reducing mortality rates. Over the years, the development of new classes of antibiotics, such as cephalosporins, tetracyclines, and macrolides, expanded the arsenal available to clinicians, enabling the treatment of various bacterial infections with increasing specificity and effectiveness. This revolution not only improved individual health outcomes but also facilitated advancements in surgical procedures and the management of chronic diseases.

What Are the Different Classes of Antibiotics and Their Mechanisms?

Antibiotics are classified into several categories based on their chemical structure and mechanism of action. Beta-lactams, including penicillins and cephalosporins, disrupt bacterial cell wall synthesis, leading to cell lysis and death. Tetracyclines inhibit protein synthesis by binding to the bacterial ribosome, preventing the production of essential proteins. Macrolides, such as erythromycin, also target bacterial ribosomes but do so by a different mechanism, which makes them effective against a different spectrum of bacteria. Aminoglycosides interfere with protein synthesis as well but are particularly effective against aerobic gram-negative bacteria. Fluoroquinolones, like ciprofloxacin, inhibit DNA replication by targeting bacterial DNA gyrase and topoisomerase IV. Each class of antibiotics offers unique advantages and is used to target specific types of bacterial infections, allowing for more tailored and effective treatments.

What Challenges Are Associated with Antibiotic Resistance?

Antibiotic resistance is one of the most significant challenges facing modern medicine. Overuse and misuse of antibiotics in human medicine and agriculture have accelerated the development of resistant bacterial strains. When bacteria are exposed to antibiotics, they can evolve mechanisms to survive, such as producing enzymes that deactivate the drug, altering the drug’s target site, or pumping the drug out of the cell. Resistant infections are harder to treat, often requiring more potent antibiotics, longer treatment durations, and in some cases, leading to increased mortality. The spread of multidrug-resistant organisms, such as methicillin-resistant Staphylococcus aureus (MRSA) and carbapenem-resistant Enterobacteriaceae (CRE), underscores the urgency of this issue. Efforts to combat antibiotic resistance include the development of new antibiotics, the implementation of antibiotic stewardship programs to optimize the use of existing antibiotics, and global initiatives to reduce antibiotic misuse and promote research into alternative therapies.

What Factors Are Driving the Growth in the Antibiotics Market?

The growth in the antibiotics market is driven by several factors. Increasing prevalence of bacterial infections, particularly in developing regions with high population densities and limited access to healthcare, is a significant driver. Advances in diagnostic technologies are improving the detection and identification of bacterial pathogens, leading to more targeted antibiotic therapies. The rise of hospital-acquired infections, which are often resistant to multiple antibiotics, necessitates the development and use of newer, more effective treatments. Additionally, ongoing research and development efforts are focused on discovering novel antibiotics with unique mechanisms of action to overcome existing resistance issues. Regulatory support and funding from governments and health organizations are also bolstering the antibiotics market by facilitating the research, approval, and commercialization of new antibiotic agents. Furthermore, the expansion of healthcare infrastructure and increased healthcare spending in emerging economies are contributing to greater access to and demand for antibiotics, thereby driving market growth.

SCOPE OF STUDY:

The report analyzes the Antibiotics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Drug Class (Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline, Other Drug Classes); Route of Administration (Parenteral, Oral, Other Routes of Administration)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 209 Featured) -

  • Abbott Laboratories, Inc.
  • Allergan PLC
  • Aurobindo Pharma Ltd.
  • Bayer AG
  • Eli Lilly and Company
  • F. Hoffmann-La Roche AG
  • GlaxoSmithKline PLC
  • Lupin Pharmaceuticals, Inc.
  • Merck & Co., Inc.
  • Mylan NV
  • Novartis International AG
  • Pfizer, Inc.
  • Sanofi
  • Shionogi, Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Antibiotics - Global Key Competitors Percentage Market Share in 2025 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Rising Incidence of Bacterial Infections Throws the Spotlight on Antibiotics
    • Advances in Antibiotic Drug Discovery and Development Spurs Growth in Antibiotics Market
    • Increasing Use in Livestock and Agriculture Expands Addressable Market Opportunity
    • Growing Threat of Antibiotic Resistance Strengthens Business Case for Novel Antibiotics
    • Regulatory Approvals for New Antibiotic Classes Generates Demand for Advanced Therapeutics
    • Technological Innovations in Antibiotic Formulation Drives Adoption of Improved Treatments
    • Expansion of Antibiotic Stewardship Programs Sustains Growth in Antibiotics Market
    • Rising Demand for Antibiotics in Emerging Economies Accelerates Market Demand
    • Development of Narrow-Spectrum Antibiotics Spurs Innovation in Targeted Therapy
    • Increasing Investment in Antibiotic Research and Development Propels Market Growth
    • Growing Awareness of Infection Control Measures Strengthens Market Potential for Antibiotics
    • Development of Combination Therapies to Combat Resistance Generates Interest in Antibiotics
    • Increasing Focus on Pediatric and Geriatric Antibiotic Treatments Drives Adoption
    • Expansion of Applications in Healthcare-Associated Infections Spurs Market Growth
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Antibiotics Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Antibiotics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 4: World 15-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2015, 2025 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Penicillin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Penicillin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 7: World 15-Year Perspective for Penicillin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Cephalosporin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Cephalosporin by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 10: World 15-Year Perspective for Cephalosporin by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Macrolides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Macrolides by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 13: World 15-Year Perspective for Macrolides by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Fluoroquinolones by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Fluoroquinolones by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 16: World 15-Year Perspective for Fluoroquinolones by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Tetracycline by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Tetracycline by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 19: World 15-Year Perspective for Tetracycline by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Other Drug Classes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 22: World 15-Year Perspective for Other Drug Classes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 23: World Recent Past, Current & Future Analysis for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 24: World Historic Review for Parenteral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 25: World 15-Year Perspective for Parenteral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 26: World Recent Past, Current & Future Analysis for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 27: World Historic Review for Oral by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 28: World 15-Year Perspective for Oral by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030
    • TABLE 29: World Recent Past, Current & Future Analysis for Other Routes of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 30: World Historic Review for Other Routes of Administration by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 31: World 15-Year Perspective for Other Routes of Administration by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2015, 2025 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
    • TABLE 32: USA Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 33: USA Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 34: USA 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 35: USA Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 36: USA Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 37: USA 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • CANADA
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 40: Canada 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 41: Canada Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 42: Canada Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 43: Canada 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • JAPAN
    • Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 46: Japan 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 49: Japan 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • CHINA
    • Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 52: China 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 53: China Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 55: China 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • EUROPE
    • Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
    • TABLE 56: Europe Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 57: Europe Historic Review for Antibiotics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 58: Europe 15-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2015, 2025 & 2030
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 61: Europe 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 64: Europe 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • FRANCE
    • Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
    • TABLE 65: France Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 66: France Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 67: France 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 68: France Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 69: France Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 70: France 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • GERMANY
    • Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
    • TABLE 71: Germany Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 72: Germany Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 73: Germany 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 74: Germany Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 75: Germany Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 76: Germany 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • ITALY
    • TABLE 77: Italy Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 78: Italy Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 79: Italy 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 80: Italy Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 81: Italy Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 82: Italy 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • UNITED KINGDOM
    • Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
    • TABLE 83: UK Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 84: UK Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 85: UK 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 86: UK Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 87: UK Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 88: UK 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • SPAIN
    • TABLE 89: Spain Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 90: Spain Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 91: Spain 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 92: Spain Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 93: Spain Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 94: Spain 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • RUSSIA
    • TABLE 95: Russia Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 96: Russia Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 97: Russia 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 98: Russia Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 99: Russia Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 100: Russia 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • REST OF EUROPE
    • TABLE 101: Rest of Europe Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 102: Rest of Europe Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 103: Rest of Europe 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 104: Rest of Europe Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 105: Rest of Europe Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 106: Rest of Europe 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • ASIA-PACIFIC
    • Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
    • TABLE 107: Asia-Pacific Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 108: Asia-Pacific Historic Review for Antibiotics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 109: Asia-Pacific 15-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2015, 2025 & 2030
    • TABLE 110: Asia-Pacific Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 111: Asia-Pacific Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 112: Asia-Pacific 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 113: Asia-Pacific Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 114: Asia-Pacific Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 115: Asia-Pacific 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • AUSTRALIA
    • Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
    • TABLE 116: Australia Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 117: Australia Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 118: Australia 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 119: Australia Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 120: Australia Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 121: Australia 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • INDIA
    • Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
    • TABLE 122: India Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 123: India Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 124: India 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 125: India Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 126: India Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 127: India 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • SOUTH KOREA
    • TABLE 128: South Korea Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 129: South Korea Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 130: South Korea 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 131: South Korea Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 132: South Korea Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 133: South Korea 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • REST OF ASIA-PACIFIC
    • TABLE 134: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 135: Rest of Asia-Pacific Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 136: Rest of Asia-Pacific 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 137: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 138: Rest of Asia-Pacific Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 139: Rest of Asia-Pacific 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • LATIN AMERICA
    • Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
    • TABLE 140: Latin America Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 141: Latin America Historic Review for Antibiotics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 142: Latin America 15-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2015, 2025 & 2030
    • TABLE 143: Latin America Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 144: Latin America Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 145: Latin America 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 146: Latin America Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 147: Latin America Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 148: Latin America 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • ARGENTINA
    • TABLE 149: Argentina Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 150: Argentina Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 151: Argentina 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 152: Argentina Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 153: Argentina Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 154: Argentina 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • BRAZIL
    • TABLE 155: Brazil Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 156: Brazil Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 157: Brazil 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 158: Brazil Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 159: Brazil Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 160: Brazil 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • MEXICO
    • TABLE 161: Mexico Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 162: Mexico Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 163: Mexico 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 164: Mexico Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 165: Mexico Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 166: Mexico 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • REST OF LATIN AMERICA
    • TABLE 167: Rest of Latin America Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 168: Rest of Latin America Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 169: Rest of Latin America 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 170: Rest of Latin America Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 171: Rest of Latin America Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 172: Rest of Latin America 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • MIDDLE EAST
    • Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
    • TABLE 173: Middle East Recent Past, Current & Future Analysis for Antibiotics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
    • TABLE 174: Middle East Historic Review for Antibiotics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 175: Middle East 15-Year Perspective for Antibiotics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2015, 2025 & 2030
    • TABLE 176: Middle East Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 177: Middle East Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 178: Middle East 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 179: Middle East Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 180: Middle East Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 181: Middle East 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • IRAN
    • TABLE 182: Iran Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 183: Iran Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 184: Iran 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 185: Iran Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 186: Iran Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 187: Iran 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • ISRAEL
    • TABLE 188: Israel Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 189: Israel Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 190: Israel 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 191: Israel Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 192: Israel Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 193: Israel 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • SAUDI ARABIA
    • TABLE 194: Saudi Arabia Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 195: Saudi Arabia Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 196: Saudi Arabia 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 197: Saudi Arabia Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 198: Saudi Arabia Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 199: Saudi Arabia 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • UNITED ARAB EMIRATES
    • TABLE 200: UAE Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 201: UAE Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 202: UAE 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 203: UAE Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 204: UAE Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 205: UAE 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • REST OF MIDDLE EAST
    • TABLE 206: Rest of Middle East Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 207: Rest of Middle East Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 208: Rest of Middle East 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 209: Rest of Middle East Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 210: Rest of Middle East Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 211: Rest of Middle East 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030
  • AFRICA
    • Antibiotics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
    • TABLE 212: Africa Recent Past, Current & Future Analysis for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 213: Africa Historic Review for Antibiotics by Drug Class - Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 214: Africa 15-Year Perspective for Antibiotics by Drug Class - Percentage Breakdown of Value Sales for Penicillin, Cephalosporin, Macrolides, Fluoroquinolones, Tetracycline and Other Drug Classes for the Years 2015, 2025 & 2030
    • TABLE 215: Africa Recent Past, Current & Future Analysis for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
    • TABLE 216: Africa Historic Review for Antibiotics by Route Of Administration - Parenteral, Oral and Other Routes of Administration Markets - Independent Analysis of Annual Sales in US$ Million for Years 2015 through 2023 and % CAGR
    • TABLE 217: Africa 15-Year Perspective for Antibiotics by Route Of Administration - Percentage Breakdown of Value Sales for Parenteral, Oral and Other Routes of Administration for the Years 2015, 2025 & 2030

IV. COMPETITION